![Eddie Wang](https://profiles-cardiff.imgix.net/attachments/2634?w=200&h=200&auto=format&crop=faces&fit=crop&q=90")
Yr Athro Eddie Wang
- Sylwebydd y cyfryngau
Timau a rolau for Eddie Wang
Athro Imiwnoleg Feirysol
Trosolwyg
Rwy'n Athro Imiwnoleg Firaol o fewn Grŵp Ymchwil 'Imiwnoleg Firaol' (VIRG) yr Is-adran Heintiau ac Imiwnedd, Ysgol Feddygaeth, Coleg y Gwyddorau Biofeddygol a Bywyd. Mae fy ymchwil yn cwmpasu'r bioleg a'r imiwnoleg gellog sy'n ymwneud â Cytomegalofirws Dynol (HCMV) a swyddogaeth fiolegol Derbynnydd Marwolaeth 3, aelod o'r uwch-deulu TNFR sy'n ymwneud â rheoli clefyd llidiol ac awtoimiwn. Mae rhagor o fanylion am waith HCMV i'w gweld ar dudalen we VIRG (https://www.cardiff.ac.uk/research/explore/research-units/viral-immunology-research-group).
Mae rhagor o fanylion am gyhoeddiadau ar gael ar Researchgate (https://www.researchgate.net/profile/Eddie_Wang) a Google Scholar (https://scholar.google.co.uk/citations?hl=en&user=DgvpthYAAAAJ)
Aelodaeth Broffesiynol
- Cymdeithas Imiwnoleg Prydain
- Cymdeithas Microbioleg
- Cynghorydd Gwyddonol ar gyfer Labordai Shattuck
Pwyllgorau'r Brifysgol
- Aelod o Fenter Athrawon Lleiafrifoedd Ethnig Cymru (WEMPI)
- Aelod o'r Sefydliad Ymchwil Prifysgol Imiwnedd Systemau (SIURI)
- Swyddog Meinweoedd Dynol ar gyfer Adeilad Henry Wellcome, Is-adran Heintiau ac Imiwnedd (hyd at 2025)
- Aelod o Bwyllgor Llywodraethu Ymchwil HTA Prifysgol Caerdydd (hyd at 2025)
- Thema Osgoi Imiwnedd Caerdydd ar y cyd arweinydd ar gyfer Consortiwm Imiwnoleg Coronafeirws y DU (UK-CIC)
- Cynllun GW4-PhD Panel rhestr fer/cyfweliad thema Heintiau, Imiwnedd a Thrwsio 2020/21
Cyhoeddiad
2026
- Gunn, J. L. et al., 2026. Auguries of adaptivity: LES γδ TCR ligand recognition revisited. Trends in Immunology 47 (2), pp.106-118. (10.1016/j.it.2025.10.006)
2025
- Davies, K. et al. 2025. NKG2A-mediated immune modulation of natural killer cells by Staphylococcus aureus. The Journal of Immunology 214 (12), pp.3332-3344. (10.1093/jimmun/vkaf174)
- Bentley, K. et al. 2025. Virion proteomics of genetically intact HCMV reveals a regulator of envelope glycoprotein composition that protects against humoral immunity. Proceedings of the National Academy of Sciences 122 (38) e2425622122. (10.1073/pnas.2425622122)
- Preston, H. et al. 2025. Human cytomegalovirus immune evasion of natural killer cells: a virus for all seasons?. Pathogens 14 (7) 629. (10.3390/pathogens14070629)
2024
- Litvin, U. et al., 2024. Evolution of the cytomegalovirus RL11 gene family in old world monkeys and great apes. Virus Evolution 10 (1) veae066. (10.1093/ve/veae066)
- Kite, J. et al., 2024. Downregulation of endogenous nectin1 in human keratinocytes by herpes simplex virus 1 glycoprotein D excludes superinfection but does not affect NK cell function. Journal of General Virology 105 (3)(10.1099/jgv.0.001969)
2023
- Vlachava, V. et al. 2023. HCMV-secreted glycoprotein gpUL4 inhibits TRAIL-mediated apoptosis and NK cell activation. Proceedings of the National Academy of Sciences 120 (49) e2309077120. (10.1073/pnas.2309077120)
- Rubina, A. et al. 2023. ADAM17 targeting by human cytomegalovirus remodels the cell surface proteome to simultaneously regulate multiple immune pathways. Proceedings of the National Academy of Sciences 120 (33) e2303155120. (10.1073/pnas.2303155120)
- Grant, M. D. et al., 2023. Combined anti-S1 and anti-S2 antibodies from hybrid immunity elicit potent cross-variant ADCC against SARS-CoV-2. JCI Insight 8 (15) e170681. (10.1172/jci.insight.170681)
- Luo, S. et al., 2023. The cytokine receptor DR3 identifies and promotes the activation of thymic NKT17 cells. Cellular and Molecular Life Sciences 80 (3), pp.1-12. 76. (10.1007/s00018-023-04726-7)
2022
- Morgan, H. J. et al. 2022. CD200 ectodomain shedding into the tumor microenvironment leads to NK cell dysfunction and apoptosis. Journal of Clinical Investigation 132 (21) e150750. (10.1172/JCI150750)
- Statkute, E. , Wang, E. and Stanton, R. 2022. An optimised CRISPR/Cas9 adenovirus vector (AdZ-CRISPR) for high throughput cloning of sgRNA, using enhanced sgRNA and Cas9 variants. Human Gene Therapy 33 (17-18), pp.990-1001. (10.1089/hum.2021.120)
- Crozier, T. W. et al., 2022. Quantitative proteomic analysis of SARS-CoV-2 infection of primary human airway ciliated cells and lung epithelial cells demonstrates the effectiveness of SARS-CoV-2 innate immune evasion. Wellcome Open Research 7 224. (10.12688/wellcomeopenres.17946.1)
- Fielding, C. A. et al. 2022. SARS-CoV-2 host-shutoff impacts innate NK cell functions, but antibody-dependent NK activity is strongly activated through non-spike antibodies. eLife 11 (10.7554/eLife.74489)
- Wang, E. C. , Fielding, C. A. and Stanton, R. J. 2022. Concerns over functional experiments, interpretation, and required controls. Journal of Clinical Investigation 132 (5) e157369. (10.1172/JCI157369)
- Nightingale, K. et al., 2022. Human cytomegalovirus protein RL1 degrades the antiviral factor SLFN11 via recruitment of the CRL4 E3 ubiquitin ligase complex. Proceedings of the National Academy of Sciences 119 (6) e2108173119. (10.1073/pnas.2108173119)
2021
- Wickenhagen, A. et al., 2021. A prenylated dsRNA sensor protects against severe COVID-19. Science 374 (6567), pp.535-536. (10.1126/science.abj3624)
- Vlachava, V. et al. 2021. Monoclonal antibodies targeting nonstructural viral antigens can activate ADCC against human cytomegalovirus. Journal of Clinical Investigation 131 (4) e139296. (10.1172/JCI139296)
2020
- Ahmed, R. et al., 2020. CD57+ Memory T Cells Proliferate In Vivo. Cell Reports 33 (11) 108501. (10.1016/j.celrep.2020.108501)
- Lau, B. et al., 2020. Human Cytomegalovirus long non-coding RNA1.2 suppresses extracellular release of the pro-inflammatory Cytokine IL-6 by blocking NF-κB activation. Frontiers in Cellular and Infection Microbiology 10 361. (10.3389/fcimb.2020.00361)
- Elasifer, H. et al. 2020. Downregulation of HLA-I by the molluscum contagiosum virus mc080 impacts NK-cell recognition and promotes CD8+ T-cell evasion. Journal of General Virology 101 , pp.863-872. (10.1099/jgv.0.001417)
2019
- Collins, F. L. et al. 2019. Oestrogen-deficiency induces bone loss by modulating CD14+ monocyte and CD4+ T cell DR3 expression and serum TL1A levels. BMC Musculoskeletal Disorders 20 (1) 326. (10.1186/s12891-019-2704-z)
- Nobre, L. V. et al., 2019. Human cytomegalovirus interactome analysis identifies degradation hubs, domain associations and viral protein functions. eLife 8 e49894. (10.7554/eLife.49894)
2018
- Boelen, L. et al., 2018. Inhibitory killer cell immunoglobulin-like receptors strengthen CD8+ T cell-mediated control of HIV-1, HCV, and HTLV-1. Science Immunology 3 (29) eaao2892. (10.1126/sciimmunol.aao2892)
- Patel, M. et al. 2018. HCMV-encoded NK modulators: Lessons from in vitro and in vivo genetic variation. Frontiers in Immunology 9 2214. (10.3389/fimmu.2018.02214)
- Nightingale, K. et al., 2018. High-definition analysis of host protein stability during human cytomegalovirus infection reveals antiviral factors and viral evasion mechanisms. Cell Host and Microbe 24 (3), pp.447-460.e11. (10.1016/j.chom.2018.07.011)
- Wang, E. C. Y. et al. 2018. Suppression of costimulation by human cytomegalovirus promotes evasion of cellular immune defenses. Proceedings of the National Academy of Sciences 115 (19), pp.4998-5003. (10.1073/pnas.1720950115)
- Malhotra, N. et al., 2018. RORα-expressing T regulatory cells restrain allergic skin inflammation. Science Immunology 3 (21) eaao6923. (10.1126/sciimmunol.aao6923)
2017
- Singh, R. et al. 2017. Death receptor 3 regulates distinct pathological attributes of acute versus chronic murine allergic lung inflammation. Cellular Immunology 320 , pp.62-70. (10.1016/j.cellimm.2017.09.005)
- Collins, F. L. et al. 2017. CCL3 and MMP-9 are induced by TL1A during death receptor 3 (TNFRSF25)-dependent osteoclast function and systemic bone loss. Bone 97 , pp.94-104. (10.1016/j.bone.2017.01.002)
2016
- Williams, A. et al. 2016. Novel insights into TNF receptor, DR3 and progranulin pathways in arthritis and bone remodeling. Arthritis & Rheumatology 68 (12), pp.2845-2856. (10.1002/art.39816)
- Perks, W. V. et al. 2016. Death Receptor 3 promotes chemokine directed leukocyte recruitment in acute resolving inflammation and is essential for pathological development of mesothelial fibrosis in chronic disease. American Journal of Pathology 186 (11), pp.2813-2823. (10.1016/j.ajpath.2016.07.021)
- Jia, L. et al., 2016. A novel role for TL1A/DR3 in protection against intestinal injury and infection. Journal of Immunology 197 (1), pp.377-386. (10.4049/jimmunol.1502466)
- Williams, J. et al. 2016. Characterisation of Death Receptor 3 dependent aortic changes during inflammatory arthritis. Pharmacology Research & Perspectives 4 (4) e0024. (10.1002/prp2.240)
2015
- Collins, F. L. et al., 2015. Death Receptor 3 (TNFRSF25) Increases mineral apposition by osteoblasts and region specific new bone formation in the axial skeleton of male DBA/1 mice. Journal of Immunology Research 2015 , pp.-. 901679. (10.1155/2015/901679)
- Wilkinson, G. W. G. et al. 2015. Human cytomegalovirus: taking the strain. Medical Microbiology and Immunology 204 (3), pp.273-284. (10.1007/s00430-015-0411-4)
2014
- Wang, E. C. Y. et al. 2014. Regulation of early cartilage destruction in inflammatory arthritis by death receptor 3. Arthritis and Rheumatology 66 (10), pp.2762-2772. (10.1002/art.38770)
- Stanton, R. J. et al. 2014. HCMV pUL135 remodels the actin cytoskeleton to impair immune recognition of infected cells. Cell Host and Microbe 16 (2), pp.201-214. (10.1016/j.chom.2014.07.005)
- Weekes, M. et al., 2014. Quantitative temporal viromics: an approach to investigate host-pathogen interaction. Cell 157 (6), pp.1460-1472. (10.1016/j.cell.2014.04.028)
- Fielding, C. A. et al. 2014. Two novel human cytomegalovirus NK cell evasion functions target MICA for lysosomal degradation. PLoS Pathogens 10 (5) e1004058. (10.1371/journal.ppat.1004058)
2013
- Pembroke, T. et al. 2013. The paradox of NKp46+ natural killer cells: drivers of severe hepatitis C virus-induced pathology but in-vivo resistance to interferon treatment. Gut n/a (10.1136/gutjnl-2013-304472)
- Smith, W. et al., 2013. Human cytomegalovirus glycoprotein UL141 targets the TRAIL death receptors to thwart host innate antiviral defenses. Cell Host & Microbe 13 (3), pp.324-335. (10.1016/j.chom.2013.02.003)
2012
- Prod'homme, V. et al. 2012. Human cytomegalovirus UL40 signal peptide regulates cell surface expression of the NK cell ligands HLA-E and gpUL18. The Journal of Immunology 188 (6), pp.2794-2804. (10.4049/jimmunol.1102068)
- Al-Lamki, R. S. et al., 2012. DR3 signaling protects against cisplatin nephrotoxicity mediated by tumor necrosis factor. American Journal of Pathology 180 (4), pp.1454-1464. (10.1016/j.ajpath.2012.01.003)
- Calder, C. J. and Wang, E. C. Y. 2012. An essential role for death receptor 3 in experimental autoimmune uveoretinitis [Letter]. Ocular Immunology and Inflammation 20 (3), pp.212-214. (10.3109/09273948.2012.658135)
- Coles, S. et al. 2012. Expression of CD200 on AML blasts directly suppresses memory T-cell function [Letter]. Leukemia 26 (9), pp.2148-2151. (10.1038/leu.2012.77)
- Coles, S. et al. 2012. Increased CD200 expression in acute myeloid leukemia is linked with an increased frequency of FoxP3+ regulatory T cells [Letter]. Leukemia 26 (9), pp.2146-2148. (10.1038/leu.2012.75)
- Collins, F. et al. 2012. Death receptor 3 and tl1a: A regulatory pathway of bone turnover and target for osteoporosis therapy? [Abstract]. Osteoporosis International 23 , pp.S528-S528.
- Collins, F. et al. 2012. TNF-like protein 1A/death receptor 3 pathway regulates osteoclastogenesis and is associated with erosive disease in rheumatoid arthritis. Arthritis and Rheumatism 64 (10), pp.S768-S768.
- Collins, F. et al. 2012. Death receptor 3 and Tl1a: A driving force in osteoclast differentiation and potential target for rheumatoid arthritis therapy [Abstract]. Rheumatology 51 (s3), pp.140-140. (10.1093/rheumatology/kes108)
- Pembroke, T. et al. 2012. Rapid early innate control of hepatitis C virus during IFN-α treatment compromises adaptive CD4+T-cell immunity. European Journal of Immunology 42 (9), pp.2383-2394. (10.1002/eji.201142072)
- Pembroke, T. et al. 2012. PMO-174 Intrahepatic natural killer cell phenotyping and functional analysis by fine needle aspiration in chronic HCV infection. Gut 61 (S2), pp.A144-A145. (10.1136/gutjnl-2012-302514b.174)
- Twohig, J. P. et al. 2012. The death receptor 3/TL1A pathway is essential for efficient development of antiviral CD4+ and CD8+ T-cell immunity. The FASEB Journal 26 (8), pp.3575-3586. (10.1096/fj.11-200618)
- Wang, E. C. Y. 2012. On death receptor 3 and its ligands.... Immunology 137 (1), pp.114-116. (10.1111/j.1365-2567.2012.03606.x)
2011
- Stacey, M. A. et al. 2011. IL-10 restricts activation-induced death of NK cells during acute murine cytomegalovirus infection. The Journal of Immunology 187 (6), pp.2944-2952. (10.4049/jimmunol.1101021)
- Coles, S. et al. 2011. CD200 expression suppresses natural killer cell function and directly inhibits patient anti-tumor response in acute myeloid leukemia. Leukemia 25 (5), pp.792-799. (10.1038/leu.2011.1)
- Coles, S. et al. 2011. CD200 inhibits memory Th1 cell function in acute myeloid leukaemia (AML)[Abstract]. Immunology 135 (S1), pp.178. (10.1111/j.1365-2567.2011.03534.x)
- Jones, G. W. et al. 2011. Naive and activated T cells display differential responsiveness to TL1A that affects Th17 generation, maintenance, and proliferation. The FASEB Journal 25 (1), pp.409-419. (10.1096/fj.10-166843)
- Wang, E. C. Y. 2011. CD4+ T cells, human cytomegalovirus and end-stage renal disease. Nephrology Dialysis Transplantation 26 (5), pp.1467-1470. (10.1093/ndt/gfr167)
- Wang, E. C. Y. et al. 2011. Control of early cartilage destruction in inflammatory arthritis by death receptor 3 [Abstract]. Immunology 135 (s1), pp.153-153. (10.1111/j.1365-2567.2011.03534.x)
2010
- Twohig, J. P. et al. 2010. Age-dependent maintenance of motor controland corticostriatal innervation by death receptor 3. Journal of Neuroscience 30 (10), pp.3782-3792. (10.1523/JNEUROSCI.1928-09.2010)
- Coles, S. et al. 2010. Over-expression of CD200 un acute myeloid leukemia mediates the expansion of regulatory T-lymphocytes and directly inhibits natural killer cell tumor immunity [Abstract]. Blood 116 (21), pp.218-218.
- Jones, G. W. et al. 2010. Differential responsiveness of naive and activated T cells to TL1A that affect Th17 generation, maintenance and proliferation [Abstract]. Immunology 131 (s1), pp.102-102. (10.1111/j.1365-2567.2010.03390.x)
- McLaren, J. E. et al. 2010. The TNF-like protein 1A-death receptor 3 pathway promotes macrophage foam cell formation in vitro. Journal of Immunology 184 (10), pp.5827-5834. (10.4049/jimmunol.0903782)
- Taraban, V. et al., 2010. Sustained TL1A expression modulates effector and regulatory T-cell responses and drives intestinal goblet cell hyperplasia. Mucosal Immunology 4 (2), pp.186-196. (10.1038/mi.2010.70)
- Williams, A. S. et al. 2010. Death Receptor 3 orchestrates erosive pathology in inflammatory arthritis [Poster Abstract]. Immunology 131 (s1), pp.53-53. (10.1111/j.1365-2567.2010.03390.x)
2009
- Newton, Z. et al. 2009. The role of dr3/tl1a in cartilage depletion caused by inflammatory arthritis [Abstract]. Rhuematology 48 (s1), pp.I30-I30. (10.1093/rheumatology/kep713)
- Twohig, J. P. et al. 2009. Defective B cell ontogeny and humoral immune response in mice prematurely expressing human complement receptor 2 (CR2, CD21) is similar to that seen in aging wild type mice. Molecular Immunology 46 (10), pp.2002-2013. (10.1016/j.molimm.2009.03.007)
- Williams, A. S. et al. 2009. A functional role for death receptor-3 in arthritis [Abstract]. Cytokine 48 (1-2), pp.134-134. (10.1016/j.cyto.2009.07.568)
- Williams, A. S. et al. 2009. Functional role of dr3 in inflammatory arthritis: A novel target for therapy? [Abstract]. Rheumatology 48 (s1), pp.I8-I8. (10.1093/rheumatology/kep704)
2008
- Bull, M. J. et al. 2008. The Death Receptor 3-TNF-like protein 1A pathway drives adverse bone pathology in inflammatory arthritis. Journal of Experimental Medicine 205 (11), pp.2457-2464. (10.1084/jem.20072378)
- Meylan, F. et al., 2008. The TNF-family receptor DR3 is essential for diverse T cell-mediated inflammatory diseases. Immunity 29 (1), pp.79-89. (10.1016/j.immuni.2008.04.021)
- Al-Lamki, R. S. et al., 2008. TL1A both promotes and protects from renal inflammation and injury. Journal of the American Society of Nephrology 19 (5), pp.953-960. (10.1681/ASN.2007060706)
- Chong, L. K. et al. 2008. Proliferation and interleukin 5 production by CD8hiCD57+ T cells. European Journal of Immunology 38 (4), pp.995-1000. (10.1002/eji.200737687)
- Jones, G. W. et al. 2008. TL1A negatively regulates development of T helper 17 cells [Abstract]. Rheumatology 47 (S2), pp.II20-II20. (10.1093/rheumatology/kem509)
- Jones, G. W. et al. 2008. TL1A/TNFSF15 promotes a STAT1-mediated suppression of IL-17-secreting T-helper cells [Abstract]. Immunology 125 (s1), pp.62-62. (10.1111/j.1365-2567.2008.02974.x)
- McSharry, B. P. et al. 2008. Adenovirus E3/19K promotes evasion of NK cell recognition by intracellular sequestration of the NKG2D ligands major histocompatibility complex class I chain-related proteins A and B. Journal of Virology 82 (9), pp.4585-4594. (10.1128/JVI.02251-07)
- Wilkinson, G. W. G. et al. 2008. Modulation of natural killer cells by human cytomegalovirus. Journal of Clinical Virology 41 (3), pp.206-212. (10.1016/j.jcv.2007.10.027)
- Williams, A. S. et al. 2008. The role of death receptor 3 in inflammatory arthritis [Abstract]. Immunology 125 , pp.34-34. (10.1111/j.1365-2567.2008.02974.x)
2007
- Stanton, R. J. et al. 2007. Cytomegalovirus destruction of focal adhesions revealed in a high-throughput Western blot analysis of cellular protein expression. Journal of Virology 81 (15), pp.7860-7872. (10.1128/JVI.02247-06)
- Prod'homme, V. et al. 2007. The Human Cytomegalovirus MHC Class I Homolog UL18 Inhibits LIR-1+ but Activates LIR-1- NK Cells. The Journal of Immunology 178 (7), pp.4473-4481.
- Jones, G. W. et al. 2007. TL1A counteracts the IL-6 control of the STAT3-mediated development of T helper 17 cells [Abstract]. Cytokine 39 (1), pp.18-19.
2006
- Omidvar, N. et al. 2006. Expression of glycosylphosphatidylinositol-anchored CD59 on target cells enhances human NK cell-mediated cytotoxicity. Journal of immunology 176 (5), pp.2915-2923.
2005
- Griffin, C. et al., 2005. Characterization of a highly glycosylated form of the human cytomegalovirus HLA class I homologue gpUL18. Journal of General Virology 86 (11), pp.2999-3008. (10.1099/vir.0.81126-0)
- Siebert, S. et al. 2005. Reduced tumor necrosis factor signaling in primary human fibroblasts containing a tumor necrosis factor receptor superfamily 1A mutant. Arthritis & Rheumatism 52 (4), pp.1287-1282. (10.1002/art.20955)
- Tomasec, P. et al. 2005. Downregulation of natural killer cell-activating ligand CD155 by human cytomegalovirus UL141. Nature Immunology 6 (2), pp.181-188. (10.1038/ni1156)
- Vedhara, K. and Wang, E. C. Y. 2005. Assessment of the immune system in human psychoneuroimmunology. In: Vedhara, K. and Irwin, M. R. eds. Human Psychneuroimmunology. Oxford: Oxford University Press. , pp.53-80.
2002
- Wang, E. C. Y. et al. 2002. UL40-mediated NK evasion during productive infection with human cytomegalovirus. Proceedings of the National Academy of Sciences 99 (11), pp.7570-7575. (10.1073/pnas.112680099)
2001
- Wang, E. C. Y. et al. 2001. DR3 regulates negative selection during thymocyte development. Molecular and cellular biology 21 (10), pp.3451-61. (10.1128/MCB.21.10.3451-3461.2001)
- Wang, E. C. Y. et al. 2001. Genomic structure, expression, and chromosome mapping of the mouse homologue for the WSL-1 (DR3, Apo3, TRAMP, LARD, TR3, TNFRSF12) gene. Immunogenetics 53 (1), pp.59-63. (10.1007/s002510000290)
- Lawson, T. et al. 2001. Functional differences between influenza A-specific cytotoxic T lymphocyte clones expressing dominant and subdominant TCR. International Immunology 13 (11), pp.1383-1390. (10.1093/intimm/13.11.1383)
1998
- Wang, E. C. Y. 1998. Sorting of human peripheral blood T-cell subsets using immunomagnetic beads. In: Pound, J. D. ed. Immunochemical Protocols. Vol. 80, Methods in Molecular Biology Vol. 2.Humana Press. , pp.365-376. (10.1007/978-1-59259-257-9_37)
1992
- Wang, E. C. Y. , Borysiewicz, L. K. and Weetman, A. P. 1992. Cell sorting using immunomagnetic beads. In: Manson, M. M. ed. Immunochemical Protocols. Methods in Molecular Biology Vol. 10.Totowa, NJ: Humana Press. , pp.347-358.
Adrannau llyfrau
- Vedhara, K. and Wang, E. C. Y. 2005. Assessment of the immune system in human psychoneuroimmunology. In: Vedhara, K. and Irwin, M. R. eds. Human Psychneuroimmunology. Oxford: Oxford University Press. , pp.53-80.
- Wang, E. C. Y. 1998. Sorting of human peripheral blood T-cell subsets using immunomagnetic beads. In: Pound, J. D. ed. Immunochemical Protocols. Vol. 80, Methods in Molecular Biology Vol. 2.Humana Press. , pp.365-376. (10.1007/978-1-59259-257-9_37)
- Wang, E. C. Y. , Borysiewicz, L. K. and Weetman, A. P. 1992. Cell sorting using immunomagnetic beads. In: Manson, M. M. ed. Immunochemical Protocols. Methods in Molecular Biology Vol. 10.Totowa, NJ: Humana Press. , pp.347-358.
Erthyglau
- Gunn, J. L. et al., 2026. Auguries of adaptivity: LES γδ TCR ligand recognition revisited. Trends in Immunology 47 (2), pp.106-118. (10.1016/j.it.2025.10.006)
- Davies, K. et al. 2025. NKG2A-mediated immune modulation of natural killer cells by Staphylococcus aureus. The Journal of Immunology 214 (12), pp.3332-3344. (10.1093/jimmun/vkaf174)
- Bentley, K. et al. 2025. Virion proteomics of genetically intact HCMV reveals a regulator of envelope glycoprotein composition that protects against humoral immunity. Proceedings of the National Academy of Sciences 122 (38) e2425622122. (10.1073/pnas.2425622122)
- Preston, H. et al. 2025. Human cytomegalovirus immune evasion of natural killer cells: a virus for all seasons?. Pathogens 14 (7) 629. (10.3390/pathogens14070629)
- Litvin, U. et al., 2024. Evolution of the cytomegalovirus RL11 gene family in old world monkeys and great apes. Virus Evolution 10 (1) veae066. (10.1093/ve/veae066)
- Kite, J. et al., 2024. Downregulation of endogenous nectin1 in human keratinocytes by herpes simplex virus 1 glycoprotein D excludes superinfection but does not affect NK cell function. Journal of General Virology 105 (3)(10.1099/jgv.0.001969)
- Vlachava, V. et al. 2023. HCMV-secreted glycoprotein gpUL4 inhibits TRAIL-mediated apoptosis and NK cell activation. Proceedings of the National Academy of Sciences 120 (49) e2309077120. (10.1073/pnas.2309077120)
- Rubina, A. et al. 2023. ADAM17 targeting by human cytomegalovirus remodels the cell surface proteome to simultaneously regulate multiple immune pathways. Proceedings of the National Academy of Sciences 120 (33) e2303155120. (10.1073/pnas.2303155120)
- Grant, M. D. et al., 2023. Combined anti-S1 and anti-S2 antibodies from hybrid immunity elicit potent cross-variant ADCC against SARS-CoV-2. JCI Insight 8 (15) e170681. (10.1172/jci.insight.170681)
- Luo, S. et al., 2023. The cytokine receptor DR3 identifies and promotes the activation of thymic NKT17 cells. Cellular and Molecular Life Sciences 80 (3), pp.1-12. 76. (10.1007/s00018-023-04726-7)
- Morgan, H. J. et al. 2022. CD200 ectodomain shedding into the tumor microenvironment leads to NK cell dysfunction and apoptosis. Journal of Clinical Investigation 132 (21) e150750. (10.1172/JCI150750)
- Statkute, E. , Wang, E. and Stanton, R. 2022. An optimised CRISPR/Cas9 adenovirus vector (AdZ-CRISPR) for high throughput cloning of sgRNA, using enhanced sgRNA and Cas9 variants. Human Gene Therapy 33 (17-18), pp.990-1001. (10.1089/hum.2021.120)
- Crozier, T. W. et al., 2022. Quantitative proteomic analysis of SARS-CoV-2 infection of primary human airway ciliated cells and lung epithelial cells demonstrates the effectiveness of SARS-CoV-2 innate immune evasion. Wellcome Open Research 7 224. (10.12688/wellcomeopenres.17946.1)
- Fielding, C. A. et al. 2022. SARS-CoV-2 host-shutoff impacts innate NK cell functions, but antibody-dependent NK activity is strongly activated through non-spike antibodies. eLife 11 (10.7554/eLife.74489)
- Wang, E. C. , Fielding, C. A. and Stanton, R. J. 2022. Concerns over functional experiments, interpretation, and required controls. Journal of Clinical Investigation 132 (5) e157369. (10.1172/JCI157369)
- Nightingale, K. et al., 2022. Human cytomegalovirus protein RL1 degrades the antiviral factor SLFN11 via recruitment of the CRL4 E3 ubiquitin ligase complex. Proceedings of the National Academy of Sciences 119 (6) e2108173119. (10.1073/pnas.2108173119)
- Wickenhagen, A. et al., 2021. A prenylated dsRNA sensor protects against severe COVID-19. Science 374 (6567), pp.535-536. (10.1126/science.abj3624)
- Vlachava, V. et al. 2021. Monoclonal antibodies targeting nonstructural viral antigens can activate ADCC against human cytomegalovirus. Journal of Clinical Investigation 131 (4) e139296. (10.1172/JCI139296)
- Ahmed, R. et al., 2020. CD57+ Memory T Cells Proliferate In Vivo. Cell Reports 33 (11) 108501. (10.1016/j.celrep.2020.108501)
- Lau, B. et al., 2020. Human Cytomegalovirus long non-coding RNA1.2 suppresses extracellular release of the pro-inflammatory Cytokine IL-6 by blocking NF-κB activation. Frontiers in Cellular and Infection Microbiology 10 361. (10.3389/fcimb.2020.00361)
- Elasifer, H. et al. 2020. Downregulation of HLA-I by the molluscum contagiosum virus mc080 impacts NK-cell recognition and promotes CD8+ T-cell evasion. Journal of General Virology 101 , pp.863-872. (10.1099/jgv.0.001417)
- Collins, F. L. et al. 2019. Oestrogen-deficiency induces bone loss by modulating CD14+ monocyte and CD4+ T cell DR3 expression and serum TL1A levels. BMC Musculoskeletal Disorders 20 (1) 326. (10.1186/s12891-019-2704-z)
- Nobre, L. V. et al., 2019. Human cytomegalovirus interactome analysis identifies degradation hubs, domain associations and viral protein functions. eLife 8 e49894. (10.7554/eLife.49894)
- Boelen, L. et al., 2018. Inhibitory killer cell immunoglobulin-like receptors strengthen CD8+ T cell-mediated control of HIV-1, HCV, and HTLV-1. Science Immunology 3 (29) eaao2892. (10.1126/sciimmunol.aao2892)
- Patel, M. et al. 2018. HCMV-encoded NK modulators: Lessons from in vitro and in vivo genetic variation. Frontiers in Immunology 9 2214. (10.3389/fimmu.2018.02214)
- Nightingale, K. et al., 2018. High-definition analysis of host protein stability during human cytomegalovirus infection reveals antiviral factors and viral evasion mechanisms. Cell Host and Microbe 24 (3), pp.447-460.e11. (10.1016/j.chom.2018.07.011)
- Wang, E. C. Y. et al. 2018. Suppression of costimulation by human cytomegalovirus promotes evasion of cellular immune defenses. Proceedings of the National Academy of Sciences 115 (19), pp.4998-5003. (10.1073/pnas.1720950115)
- Malhotra, N. et al., 2018. RORα-expressing T regulatory cells restrain allergic skin inflammation. Science Immunology 3 (21) eaao6923. (10.1126/sciimmunol.aao6923)
- Singh, R. et al. 2017. Death receptor 3 regulates distinct pathological attributes of acute versus chronic murine allergic lung inflammation. Cellular Immunology 320 , pp.62-70. (10.1016/j.cellimm.2017.09.005)
- Collins, F. L. et al. 2017. CCL3 and MMP-9 are induced by TL1A during death receptor 3 (TNFRSF25)-dependent osteoclast function and systemic bone loss. Bone 97 , pp.94-104. (10.1016/j.bone.2017.01.002)
- Williams, A. et al. 2016. Novel insights into TNF receptor, DR3 and progranulin pathways in arthritis and bone remodeling. Arthritis & Rheumatology 68 (12), pp.2845-2856. (10.1002/art.39816)
- Perks, W. V. et al. 2016. Death Receptor 3 promotes chemokine directed leukocyte recruitment in acute resolving inflammation and is essential for pathological development of mesothelial fibrosis in chronic disease. American Journal of Pathology 186 (11), pp.2813-2823. (10.1016/j.ajpath.2016.07.021)
- Jia, L. et al., 2016. A novel role for TL1A/DR3 in protection against intestinal injury and infection. Journal of Immunology 197 (1), pp.377-386. (10.4049/jimmunol.1502466)
- Williams, J. et al. 2016. Characterisation of Death Receptor 3 dependent aortic changes during inflammatory arthritis. Pharmacology Research & Perspectives 4 (4) e0024. (10.1002/prp2.240)
- Collins, F. L. et al., 2015. Death Receptor 3 (TNFRSF25) Increases mineral apposition by osteoblasts and region specific new bone formation in the axial skeleton of male DBA/1 mice. Journal of Immunology Research 2015 , pp.-. 901679. (10.1155/2015/901679)
- Wilkinson, G. W. G. et al. 2015. Human cytomegalovirus: taking the strain. Medical Microbiology and Immunology 204 (3), pp.273-284. (10.1007/s00430-015-0411-4)
- Wang, E. C. Y. et al. 2014. Regulation of early cartilage destruction in inflammatory arthritis by death receptor 3. Arthritis and Rheumatology 66 (10), pp.2762-2772. (10.1002/art.38770)
- Stanton, R. J. et al. 2014. HCMV pUL135 remodels the actin cytoskeleton to impair immune recognition of infected cells. Cell Host and Microbe 16 (2), pp.201-214. (10.1016/j.chom.2014.07.005)
- Weekes, M. et al., 2014. Quantitative temporal viromics: an approach to investigate host-pathogen interaction. Cell 157 (6), pp.1460-1472. (10.1016/j.cell.2014.04.028)
- Fielding, C. A. et al. 2014. Two novel human cytomegalovirus NK cell evasion functions target MICA for lysosomal degradation. PLoS Pathogens 10 (5) e1004058. (10.1371/journal.ppat.1004058)
- Pembroke, T. et al. 2013. The paradox of NKp46+ natural killer cells: drivers of severe hepatitis C virus-induced pathology but in-vivo resistance to interferon treatment. Gut n/a (10.1136/gutjnl-2013-304472)
- Smith, W. et al., 2013. Human cytomegalovirus glycoprotein UL141 targets the TRAIL death receptors to thwart host innate antiviral defenses. Cell Host & Microbe 13 (3), pp.324-335. (10.1016/j.chom.2013.02.003)
- Prod'homme, V. et al. 2012. Human cytomegalovirus UL40 signal peptide regulates cell surface expression of the NK cell ligands HLA-E and gpUL18. The Journal of Immunology 188 (6), pp.2794-2804. (10.4049/jimmunol.1102068)
- Al-Lamki, R. S. et al., 2012. DR3 signaling protects against cisplatin nephrotoxicity mediated by tumor necrosis factor. American Journal of Pathology 180 (4), pp.1454-1464. (10.1016/j.ajpath.2012.01.003)
- Calder, C. J. and Wang, E. C. Y. 2012. An essential role for death receptor 3 in experimental autoimmune uveoretinitis [Letter]. Ocular Immunology and Inflammation 20 (3), pp.212-214. (10.3109/09273948.2012.658135)
- Coles, S. et al. 2012. Expression of CD200 on AML blasts directly suppresses memory T-cell function [Letter]. Leukemia 26 (9), pp.2148-2151. (10.1038/leu.2012.77)
- Coles, S. et al. 2012. Increased CD200 expression in acute myeloid leukemia is linked with an increased frequency of FoxP3+ regulatory T cells [Letter]. Leukemia 26 (9), pp.2146-2148. (10.1038/leu.2012.75)
- Collins, F. et al. 2012. Death receptor 3 and tl1a: A regulatory pathway of bone turnover and target for osteoporosis therapy? [Abstract]. Osteoporosis International 23 , pp.S528-S528.
- Collins, F. et al. 2012. TNF-like protein 1A/death receptor 3 pathway regulates osteoclastogenesis and is associated with erosive disease in rheumatoid arthritis. Arthritis and Rheumatism 64 (10), pp.S768-S768.
- Collins, F. et al. 2012. Death receptor 3 and Tl1a: A driving force in osteoclast differentiation and potential target for rheumatoid arthritis therapy [Abstract]. Rheumatology 51 (s3), pp.140-140. (10.1093/rheumatology/kes108)
- Pembroke, T. et al. 2012. Rapid early innate control of hepatitis C virus during IFN-α treatment compromises adaptive CD4+T-cell immunity. European Journal of Immunology 42 (9), pp.2383-2394. (10.1002/eji.201142072)
- Pembroke, T. et al. 2012. PMO-174 Intrahepatic natural killer cell phenotyping and functional analysis by fine needle aspiration in chronic HCV infection. Gut 61 (S2), pp.A144-A145. (10.1136/gutjnl-2012-302514b.174)
- Twohig, J. P. et al. 2012. The death receptor 3/TL1A pathway is essential for efficient development of antiviral CD4+ and CD8+ T-cell immunity. The FASEB Journal 26 (8), pp.3575-3586. (10.1096/fj.11-200618)
- Wang, E. C. Y. 2012. On death receptor 3 and its ligands.... Immunology 137 (1), pp.114-116. (10.1111/j.1365-2567.2012.03606.x)
- Stacey, M. A. et al. 2011. IL-10 restricts activation-induced death of NK cells during acute murine cytomegalovirus infection. The Journal of Immunology 187 (6), pp.2944-2952. (10.4049/jimmunol.1101021)
- Coles, S. et al. 2011. CD200 expression suppresses natural killer cell function and directly inhibits patient anti-tumor response in acute myeloid leukemia. Leukemia 25 (5), pp.792-799. (10.1038/leu.2011.1)
- Coles, S. et al. 2011. CD200 inhibits memory Th1 cell function in acute myeloid leukaemia (AML)[Abstract]. Immunology 135 (S1), pp.178. (10.1111/j.1365-2567.2011.03534.x)
- Jones, G. W. et al. 2011. Naive and activated T cells display differential responsiveness to TL1A that affects Th17 generation, maintenance, and proliferation. The FASEB Journal 25 (1), pp.409-419. (10.1096/fj.10-166843)
- Wang, E. C. Y. 2011. CD4+ T cells, human cytomegalovirus and end-stage renal disease. Nephrology Dialysis Transplantation 26 (5), pp.1467-1470. (10.1093/ndt/gfr167)
- Wang, E. C. Y. et al. 2011. Control of early cartilage destruction in inflammatory arthritis by death receptor 3 [Abstract]. Immunology 135 (s1), pp.153-153. (10.1111/j.1365-2567.2011.03534.x)
- Twohig, J. P. et al. 2010. Age-dependent maintenance of motor controland corticostriatal innervation by death receptor 3. Journal of Neuroscience 30 (10), pp.3782-3792. (10.1523/JNEUROSCI.1928-09.2010)
- Coles, S. et al. 2010. Over-expression of CD200 un acute myeloid leukemia mediates the expansion of regulatory T-lymphocytes and directly inhibits natural killer cell tumor immunity [Abstract]. Blood 116 (21), pp.218-218.
- Jones, G. W. et al. 2010. Differential responsiveness of naive and activated T cells to TL1A that affect Th17 generation, maintenance and proliferation [Abstract]. Immunology 131 (s1), pp.102-102. (10.1111/j.1365-2567.2010.03390.x)
- McLaren, J. E. et al. 2010. The TNF-like protein 1A-death receptor 3 pathway promotes macrophage foam cell formation in vitro. Journal of Immunology 184 (10), pp.5827-5834. (10.4049/jimmunol.0903782)
- Taraban, V. et al., 2010. Sustained TL1A expression modulates effector and regulatory T-cell responses and drives intestinal goblet cell hyperplasia. Mucosal Immunology 4 (2), pp.186-196. (10.1038/mi.2010.70)
- Williams, A. S. et al. 2010. Death Receptor 3 orchestrates erosive pathology in inflammatory arthritis [Poster Abstract]. Immunology 131 (s1), pp.53-53. (10.1111/j.1365-2567.2010.03390.x)
- Newton, Z. et al. 2009. The role of dr3/tl1a in cartilage depletion caused by inflammatory arthritis [Abstract]. Rhuematology 48 (s1), pp.I30-I30. (10.1093/rheumatology/kep713)
- Twohig, J. P. et al. 2009. Defective B cell ontogeny and humoral immune response in mice prematurely expressing human complement receptor 2 (CR2, CD21) is similar to that seen in aging wild type mice. Molecular Immunology 46 (10), pp.2002-2013. (10.1016/j.molimm.2009.03.007)
- Williams, A. S. et al. 2009. A functional role for death receptor-3 in arthritis [Abstract]. Cytokine 48 (1-2), pp.134-134. (10.1016/j.cyto.2009.07.568)
- Williams, A. S. et al. 2009. Functional role of dr3 in inflammatory arthritis: A novel target for therapy? [Abstract]. Rheumatology 48 (s1), pp.I8-I8. (10.1093/rheumatology/kep704)
- Bull, M. J. et al. 2008. The Death Receptor 3-TNF-like protein 1A pathway drives adverse bone pathology in inflammatory arthritis. Journal of Experimental Medicine 205 (11), pp.2457-2464. (10.1084/jem.20072378)
- Meylan, F. et al., 2008. The TNF-family receptor DR3 is essential for diverse T cell-mediated inflammatory diseases. Immunity 29 (1), pp.79-89. (10.1016/j.immuni.2008.04.021)
- Al-Lamki, R. S. et al., 2008. TL1A both promotes and protects from renal inflammation and injury. Journal of the American Society of Nephrology 19 (5), pp.953-960. (10.1681/ASN.2007060706)
- Chong, L. K. et al. 2008. Proliferation and interleukin 5 production by CD8hiCD57+ T cells. European Journal of Immunology 38 (4), pp.995-1000. (10.1002/eji.200737687)
- Jones, G. W. et al. 2008. TL1A negatively regulates development of T helper 17 cells [Abstract]. Rheumatology 47 (S2), pp.II20-II20. (10.1093/rheumatology/kem509)
- Jones, G. W. et al. 2008. TL1A/TNFSF15 promotes a STAT1-mediated suppression of IL-17-secreting T-helper cells [Abstract]. Immunology 125 (s1), pp.62-62. (10.1111/j.1365-2567.2008.02974.x)
- McSharry, B. P. et al. 2008. Adenovirus E3/19K promotes evasion of NK cell recognition by intracellular sequestration of the NKG2D ligands major histocompatibility complex class I chain-related proteins A and B. Journal of Virology 82 (9), pp.4585-4594. (10.1128/JVI.02251-07)
- Wilkinson, G. W. G. et al. 2008. Modulation of natural killer cells by human cytomegalovirus. Journal of Clinical Virology 41 (3), pp.206-212. (10.1016/j.jcv.2007.10.027)
- Williams, A. S. et al. 2008. The role of death receptor 3 in inflammatory arthritis [Abstract]. Immunology 125 , pp.34-34. (10.1111/j.1365-2567.2008.02974.x)
- Stanton, R. J. et al. 2007. Cytomegalovirus destruction of focal adhesions revealed in a high-throughput Western blot analysis of cellular protein expression. Journal of Virology 81 (15), pp.7860-7872. (10.1128/JVI.02247-06)
- Prod'homme, V. et al. 2007. The Human Cytomegalovirus MHC Class I Homolog UL18 Inhibits LIR-1+ but Activates LIR-1- NK Cells. The Journal of Immunology 178 (7), pp.4473-4481.
- Jones, G. W. et al. 2007. TL1A counteracts the IL-6 control of the STAT3-mediated development of T helper 17 cells [Abstract]. Cytokine 39 (1), pp.18-19.
- Omidvar, N. et al. 2006. Expression of glycosylphosphatidylinositol-anchored CD59 on target cells enhances human NK cell-mediated cytotoxicity. Journal of immunology 176 (5), pp.2915-2923.
- Griffin, C. et al., 2005. Characterization of a highly glycosylated form of the human cytomegalovirus HLA class I homologue gpUL18. Journal of General Virology 86 (11), pp.2999-3008. (10.1099/vir.0.81126-0)
- Siebert, S. et al. 2005. Reduced tumor necrosis factor signaling in primary human fibroblasts containing a tumor necrosis factor receptor superfamily 1A mutant. Arthritis & Rheumatism 52 (4), pp.1287-1282. (10.1002/art.20955)
- Tomasec, P. et al. 2005. Downregulation of natural killer cell-activating ligand CD155 by human cytomegalovirus UL141. Nature Immunology 6 (2), pp.181-188. (10.1038/ni1156)
- Wang, E. C. Y. et al. 2002. UL40-mediated NK evasion during productive infection with human cytomegalovirus. Proceedings of the National Academy of Sciences 99 (11), pp.7570-7575. (10.1073/pnas.112680099)
- Wang, E. C. Y. et al. 2001. DR3 regulates negative selection during thymocyte development. Molecular and cellular biology 21 (10), pp.3451-61. (10.1128/MCB.21.10.3451-3461.2001)
- Wang, E. C. Y. et al. 2001. Genomic structure, expression, and chromosome mapping of the mouse homologue for the WSL-1 (DR3, Apo3, TRAMP, LARD, TR3, TNFRSF12) gene. Immunogenetics 53 (1), pp.59-63. (10.1007/s002510000290)
- Lawson, T. et al. 2001. Functional differences between influenza A-specific cytotoxic T lymphocyte clones expressing dominant and subdominant TCR. International Immunology 13 (11), pp.1383-1390. (10.1093/intimm/13.11.1383)
Ymchwil
THEMÂU YMCHWIL
Rwyf wedi cael diddordeb hirsefydlog mewn cytomegalofirws dynol (HCMV), herpesfirws sy'n brif achos heintus annormaleddau cynhenid ac sy'n achosi clefyd sy'n peryglu bywyd mewn derbynwyr trawsblaniad imiwnedd a chleifion AIDS. Mae HCMV yn heintio am oes ac yn imprintio ar y system imiwnedd; Adroddais yn wreiddiol ar natur oligoclonaidd ehangiadau celloedd T CD8 + CD57 + sy'n gysylltiedig â haint HCMV dros 25 mlynedd yn ôl (1-3). Rwyf wedi gwneud cyfraniad sylweddol i'n dealltwriaeth o osgoi imiwnedd HCMV gan gynnal nifer o grantiau ymchwil MRC a rhaglen Wellcome Trust i astudio hyn ers hynny. Peter Tomasec, Gavin Wilkinson a minnau oedd y cyntaf i ddiffinio'n llawn swyddogaeth osgoi NK firaol (HCMV UL40) (4, 5). Wrth archwilio gwahaniaethau rhwng straen HCMV labordy a chlinigol gyda Richard Stanton, fe wnaethom nodi ymhellach UL135, UL141, UL142 (gyda Mark Wills, Caergrawnt) ac UL148 fel swyddogaethau osgoi NK newydd (6-10). Wrth ail-werthuso'r homolog HLA-I UL18, fe wnaethom ddangos bod UL18 yn darparu ar gyfer ataliad NK sy'n ddibynnol ar LIR1 (11) a nodi US18 ac US20 fel yr imiwnoevasinau HCMV dominyddol sy'n gyfrifol am atal y ligandau actifadu celloedd NK MICA a B7-H6 (12, 13). Mae'r ymchwil fwyaf diweddar wedi dangos bod targedu ADAM17 gan UL148 ac UL148D yn newid proteom wyneb celloedd heintiedig yn ddwfn ac yn atal celloedd NK yn anuniongyrchol (14), tra bod y protein UL4 hydawdd yn blocio ymsefydlu marwolaeth celloedd ac actifadu NK a chyfryngwyd gan TRAIL (15). Mae hyn yn cynrychioli ~ hanner yr holl atalyddion NK hysbys wedi'u hamgodio gan HCMV (16-18). Arweiniodd fy hanes o ran osgoi imiwnedd at gael ei gynnwys fel cyd-arweinydd Caerdydd ar gyfer y thema Osgoi Imiwnedd ar gyfer Consortiwm Imiwnoleg Coronafeirws y DU (UK-CIC) sy'n astudio imiwnopatholeg SARS-CoV-2 (19-21).
Rwyf hefyd wedi gwneud cyfraniad sylweddol i faes ymchwil Derbynnydd Marwolaeth 3 (DR3). Mae DR3 yn aelod o'r Uwch-deulu Derbynnydd Ffactor Necrosis Tiwmor (TNFRSF) sy'n ymwneud â rheoleiddio imiwnedd. Cynhyrchais y llygoden DR3ko gyntaf (22), gan sefydlu swyddogaeth hanfodol DR3 mewn clefydau llidiol / awtoimiwn yn amrywio o arthritis llidiol (23) i glefyd llidiol y coluddyn (24) ac imiwnedd gwrthfeirysol (25) trwy reoli celloedd T (26, 27) a swyddogaeth myeloid (23, 28). Aeth therapïau biolegol yn erbyn TL1A, y ligand TNFSF ar gyfer DR3, i mewn i dreialon clinigol Cam III ar gyfer trin clefydau llidiol y coluddyn yn 2025 gyda photensial 'gorau'r dosbarth' (29, 30) ac rwy'n gynghorydd gwyddonol i gwmni sy'n datblygu therapïau sy'n targedu'r llwybr hwn.
CYLLID CYFREDOL (grantiau mawr yn unig)
2025-2033 Gwobr Darganfod Ymddiriedolaeth Wellcome "Dadansoddiad systematig o osgoi imiwnedd cytomegalofirws dynol" a ddyfarnwyd i M Weekes (Arweinydd, Prifysgol Caergrawnt), E Wang, R Stanton. £3,803,491
2025-2030 Gwobr y Sefydliad Iechyd Cenedlaethol "Rôl celloedd, antigen, a gwrthgyrff, wrth reoli haint firws trwy fecanweithiau sy'n ddibynnol ar Fc" a ddyfarnwyd i R Stanton (Arweinydd), C Fielding, V Zelek, E Wang, J Orange (Prifysgol Columbia), S Graham, M Weekes (Prifysgol Caergrawnt). ~£1.500.000
Grant Prosiect MRC 2025-2028 "Targedu coronafirws trwy fecanweithiau sy'n ddibynnol ar FC" a ddyfarnwyd i R Stanton (Arweinydd), C Fielding, E Wang, I Humphreys. (£907,456)
2023-2030 Gwobr Darganfod Ymddiriedolaeth Wellcome "Manteisio ar ymatebion imiwnedd gwrthfeirysol newydd" wedi'i dyfarnu i R Stanton (Arweinydd), E Wang (£1,976,186)
2023-2027 GW4-PhD Studenstship "Cynhyrchu celloedd lladdwr ar gyfer imiwnotherapi yn erbyn canser a phathogenau " a ddyfarnwyd i E Wang (Arwain), M Heinrich-Sevcenco, R Stanton, L Wooldridge (Bryste) (£114,536)
2021-2027 Technegydd 5 mlynedd a ariennir drwy gydweithio ar SIA Ymddiriedolaeth Wellcome a ddyfarnwyd i Ben Willcox (Prifysgol Birmingham) "Archwilio paradeimau celloedd T gamma delta cynhenid ac addasol mewn iechyd a chlefydau" (~£2m, £379,510 ohono i Gaerdydd)
CYLLID HANESYDDOL (grantiau mawr yn unig)
2022-2025 Grant Prosiect KRUK "Nodi ffactorau risg mewn cleifion trawsblaniad arennau ar gyfer clefyd a achosir gan haint cytomegalofirws dynol" dyfarnwyd i E Wang (PI), R Stanton, S Griffin (£209,986)
Grant Prosiect MRC 2020-2025 "Nodweddu dosbarth newydd o imiwnoevasin celloedd lladdwr naturiol" a ddyfarnwyd i E Wang (PI), R Stanton, D Price, S Kollnberger (£819,703)
Grant Prosiect NIHR 2021-2023 "Penderfynyddion imiwnolegol a firolegol COVID hir" a ddyfarnwyd i D Price (PI), H Davies, I Humphreys, P Morgan, R Stanton, E Wang (£744,457)
Dyfarnwyd Grant Prosiect MRC 2019-2023 "Rôl gwrthgyrff wrth alluogi rheoli haint HCMV wedi'i gyfryngu gan gelloedd" i R Stanton (PI), E Wang (£762,492)
2017-2023 Grant Cydweithredu Ymddiriedolaeth Wellcome "Dadansoddiad o pathogenesis cytomegalofirws mewn system her ddynol" a ddyfarnwyd i P Griffiths (Coleg Prifysgol Llundain). Wang wedi'i enwi yn gydweithiwr (~£1.7m, £329,728 ohono i Gaerdydd ar gyfer PDRA)
Grant Ymchwil MRC 2020-2021 "Platfform sylfaenol y DU i astudio imiwnoleg ac imiwnopatholeg COVID-19: Consortiwm Imiwnoleg Coronafeirws y DU" a ddyfarnwyd i P Moss (Prifysgol Birmingham) a 73 o Gyd-Ymchwilwyr eraill ledled y DU gan gynnwys E Wang (~£8m, £300,000 ohono i Gaerdydd am 3 swydd mewn gwahanol labordai)
2017-2021 Grant Prosiect MRC "Nodweddu systematig y parth pathogenigrwydd HCMV a gollwyd yn ddigymell o straen a ddefnyddir yn gyffredin" a ddyfarnwyd i E Wang (PI - unig ddeiliad), G Wilkinson (wedi ymddeol), P Tomasec (wedi marw) (£956,196)
2010-2018 Grant Rhaglen Ymddiriedolaeth Wellcome "Modiwleiddio imiwnedd gwesteiwr gan sytomegalofirws dynol" a ddyfarnwyd i G Wilkinson (PI), E Wang, P Tomasec (£1,062,032)
2014-2018 Grant Prosiect MRC "Ymchwiliad systematig i swyddogaeth genynnau cytomegalofirws dynol" a ddyfarnwyd i G Wilkinson (PI), E Wang, P Tomasec (£679,426)
2010-2013 Grant Prosiect MRC "Dadansoddiad o sytomegalofirws dynol math gwyllt" a ddyfarnwyd i G Wilkinson (PI), E Wang, P Tomasec (£901,468)
2009-2013 Grant Prosiect MRC "Ymchwilio i fodiwleiddio imiwnedd i haint firaol parhaus gan y derbynnydd marwolaeth 3/llwybr 1A tebyg i TNF" a ddyfarnwyd i E Wang (PI), I Humphreys (£467,078)
2007-2010 Grant Prosiect MRC "Modiwleiddio celloedd lladdwr naturiol gan cytomegalofirws dynol" a ddyfarnwyd i G Wilkinson (PI), E Wang, P Tomasec (£668,526)
2006-2009 Grant Cydweithredu MRC "Adnodd imiwnoleg gellog a firaol yng Ngholeg Meddygaeth Cymru, Prifysgol Caerdydd" a ddyfarnwyd i E Wang (PI), A Gallimore (£188,888)
2004-2009 Grant Sefydlu Gyrfa MRC "Rôl derbynnydd marwolaeth 3 mewn swyddogaeth celloedd T CD8+ ymylol" a ddyfarnwyd i E Wang (unig ddeiliad) (£643,596)
2004-2009 Grant Rhaglen Ymddiriedolaeth Wellcome "Modiwleiddio imiwnedd gan cytomegalofirws dynol" a ddyfarnwyd i G Wilkinson (PI), E Wang, P Tomasec (£789,117)
2004-2007 Grant Prosiect Ymddiriedolaeth Wellcome "Osgoi imiwnedd gan firws Epstein Barr" a ddyfarnwyd i M Rowe (PI), E Wang (£304,679)
2002-2005 Grant Prosiect Ymddiriedolaeth Wellcome "Cynhyrchu a swyddogaeth celloedd T CD8+, CD57+ a achosir gan haint HCMV" a ddyfarnwyd i E Wang (unig ddeiliad) (£167,415)
1995-1998 Cymrodoriaeth Goffa Beit "Mecanweithiau Moleciwlaidd datblygu thymocyte" a ddyfarnwyd i E Wang (unig ddeiliad) (~£135,000)
CYFEIRIADAU
1. Wang EC et al, Clin Exp Immunol 94, 297 (1993); 2. Wang EC et al, J Immunol 155, 5046 (1995); 3. Chong LK et al, Eur J Immunol 38, 995 (2008); 4. Tomasec P et al, Gwyddoniaeth 287, 1031 (2000); 5. Wang EC et al, PNAS USA 99, 7570 (2002); 6. Wills MR et al, J Immunol 175, 7457 (2005); 7. Wang EC et al, PNAS UDA 115, 4998 (2018); 8. Tomasec P, Wang EC et al, Nature Immunol 6, 181 (2005); 9. Smith W et al, Microb Gwesteiwr Cell 13, 324 (2013); 10color. Stanton RJ et al, Microb Gwesteiwr Cell 16, 201 (2014); 11color. Prod'homme V et al, J Immunol 188, 2794 (2012); 12color. Fielding CA et al, PLoS Pathog 10, e1004058 (2014); 13. Fielding CA et al, eLife 6, e22206 (2017); 14. Rubina A et al, PNAS USA 120, e2303155120 (2023); 15. Vlachava V et al, PNAS USA 120, e2309077120 (2023); 16color. Wilkinson GW et al, Med Microbiol Immunol 204, 273 (2015); 17color. Patel M et al, Front Immunol 9, 2214 (2018); 18. Preston H et al, Pathogenau 14, 629 (2025); 19. Wickenhagen A et al, Gwyddoniaeth 374, 6567 (2021); 20. Fielding CA et al, eLife 11, e74489 (2022); 21. Crozier TW et al, Wellcome Open Res 7, 224 (2022); 22. Wang EC et al, Mol Cell Biol 21, 3451 (2001); 23. Bull MJ et al, J Exp Med 205, 2457 (2008); 24. Taraban VY et al, Mucosal Immunol 4, 186 (2011); 25. Twohig JP et al, FASEB J 26, 3675 (2012); 26. Meylan F et al, Imiwnedd 29, 79 (2008); 27. Malhotra N et al, Sci Immunol 3, eaa02892 (2018); 28. Collins FL et al, BMC Musculoskel Dis 20, 326 (2019). 29. D'Amico F et al, Med 6, 100931 (2025). 30. https://www.sanofi.com/en/media-room/press-releases/2024/2024-12-17-12-30-00-2998154
Addysgu
Rwy'n darparu darlithoedd, tiwtorialau a phrosiectau ymchwil mewn Imiwnoleg a Firoleg i ystod o gyrsiau a ddarperir gan Brifysgol Caerdydd. Ar hyn o bryd, mae'r rhan fwyaf o'r rhain ar gyfer myfyrwyr meddygol (2il a 3edd flwyddyn), ond hefyd i'r cwrs Ffarmacoleg Feddygol. Rwyf hefyd yn addysgu ar yr MSc newydd mewn Imiwnoleg Glinigol Gymhwysol ac Arbrofol.
Bywgraffiad
PROFIAD GWAITH
Ebrill 2009 ymlaen Yr Is-adran Heintiau ac Imiwnedd, Ysgol Feddygaeth, Prifysgol Caerdydd
Athro: Awst 2021 ymlaen
Darllenydd: Awst 2009 i Gorff 2021
Uwch Ddarlithydd: Ebrill 2009 i Gorff 2009
Awst 2005 – Ebrill 2009 Ysgol Feddygaeth, Prifysgol Caerdydd
Uwch Ddarlithydd
Ionawr 2000 – Gorff 2005 Adran Heintiau ac Imiwnedd, Y Drindod Dewi Sant, Caerdydd
Uwch Ddarlithydd: Awst 2004 i Gorff 2005
Darlithydd: Ionawr 2000 i Gorff 2004
Hydref 1995 – Rhagfyr 1999 Cronfa Ymchwil Canser yr Ymerodrol, Llundain
Cymrawd Ymchwil Coffa Beit
Medi 1993 - Medi 1995 Adran Feddygaeth, Y Drindod Dewi Sant, Caerdydd
RA Ôl-ddoethurol
Hydref 1992 - Ionawr 1993 Adran Biocemeg Feddygol, Y Drindod Dewi Sant, Caerdydd
Cyn-PhD RA
Hydref 1989 - Awst 1993 Adran Feddygaeth, Prifysgol Caergrawnt (PhD)
PhD mewn Imiwnoleg
Anrhydeddau a dyfarniadau
2008 Gwobr Poster Diwydiant MRC, Arddangosfa Brechlynnau ac Imiwnotherapi IIB
2003 Grant Sefydlu Gyrfa MRC
1995 Cymrodoriaeth Goffa Beit ar gyfer Ymchwil Feddygol
Gwobr Cyflwyno Llafar 1992 , 7fed Cyfarfod Ymchwil Ôl-raddedig Blynyddol, Y Drindod Dewi Sant, Caerdydd
1989 Gwobr Goffa Dr. G. Fulton Roberts ar gyfer Imiwnoleg, Caergrawnt
Contact Details
Themâu ymchwil
Arbenigeddau
- Imiwnoleg cellog
- Firoleg